信邦制药：2024年，公司下属医院门急诊量超过100万人次

Group 1 - The core viewpoint of the article is that Xinbang Pharmaceutical anticipates significant growth in patient volume for 2024, with over 1 million outpatient and emergency visits, and more than 90,000 admissions and discharges [2]